Directions in the immune targeting of cancer: Lessons learned from the cancer-testis Ag NY-ESO-1

Immunology and Cell Biology

Volumn 84, Issue 3, 2006, Pages 303-317

  Nicholaou, Theo ^a   Ebert, Lisa ^a   Davis, Ian D ^a   Robson, Neil ^a   Klein, Oliver ^a   Maraskovsky, Eugene ^b   Chen, Weisan ^a   Cebon, Jonathan ^a  

^a AUSTIN HOSPITAL   (Australia)

^b CSL LIMITED   (Australia)

Author keywords

Cancer immunology; Cancer vaccine; Cancer testis Ag; Dendritic cell; ISCOMATRIX; NY ESO 1

Indexed keywords

ADJUVANT; CANCER VACCINE; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; HLA DP ANTIGEN; ISCOM; MONOCLONAL ANTIBODY; NY ESO 1 ANTIGEN; SAPONIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN FUNCTION; CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; GENE FUNCTION; GENE TARGETING; GERM CELL; HUMAN; IMMUNOGENICITY; NATURAL KILLER T CELL; NONHUMAN; NY ESO 1 GENE; ONCOGENE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE ACTIVATION; TISSUE DISTRIBUTION; TROPHOBLAST; VACCINATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE PROTEINS; NEOPLASMS; T-LYMPHOCYTES; VACCINATION;

EID: 33646083008     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2006.01446.x     Document Type: Review

References (169)

1. Chen YT Boyer AD Viars CS Tsang S Old LJ Arden KC. Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28. Cytogenet. Cell Genet. 1997 79 237 40.
2. Chen YT Scanlan MJ Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA 1997 94 1914 18.
3. Simpson AJ Caballero OL Jungbluth A Chen YT Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 2005 5 615 25.
4. Jungbluth AA Chen YT Stockert E et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int. J. Cancer 2001 92 856 60.
5. Sugita Y Wada H Fujita S et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res. 2004 64 2199 204.
6. Ross MT Grafham DV Coffey AJ et al. The DNA sequence of the human X chromosome. Nature 2005 434 325 37.
7. Ayyoub M Taub RN Keohan ML et al. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun. 2004 4 7 19.
8. Claus R Almstedt M Lubbert M. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents. Semin. Oncol. 2005 32 511 20.
9. Coral S Sigalotti L Altomonte M et al. 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin. Cancer Res. 2002 8 2690 95.
10. Coral S Sigalotti L Colizzi F et al. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J. Cell. Physiol. 2005 207 58 66.
11. Gattei V Fonsatti E Sigalotti L et al. Epigenetic immunomodulation of hematopoietic malignancies. Semin. Oncol. 2005 32 503 10.
12. Hong JA Kang Y Abdullaev Z et al. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res. 2005 65 7763 74.
13. Lee L Wang RF Wang X et al. NY-ESO-1 may be a potential target for lung cancer immunotherapy. Cancer J. Sci. Am. 1999 5 20 25.
14. Lethé B Lucas S Michaux L et al. LAGE-1, a new gene with tumor specificity. Int. J. Cancer 1998 76 903 8.
15. Sigalotti L Coral S Altomonte M et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br. J. Cancer 2002 86 979 82.
16. Sigalotti L Coral S Nardi G et al. Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma. J. Immunother. 2002 25 16 26.
17. Utsunomiya T Inoue H Tanaka F et al. Expression of cancer-testis antigen (CTA) genes in intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 2004 11 934 40.
18. Weiser TS Guo ZS Ohnmacht GA et al. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J. Immunother. 2001 24 151 61.
19. Alpen B Gure AO Scanlan MJ Old LJ Chen YT. A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved. Gene 2002 297 141 9.
20. Aradhya S Bardaro T Galgoczy P et al. Multiple pathogenic and benign genomic rearrangements occur at a 35 kb duplication involving the NEMO and LAGE2 genes. Hum. Mol. Genet. 2001 10 2557 67.
21. Smahi A Courtois G Rabia SH et al. The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum. Mol. Genet. 2002 11 2371 5.
22. Satie AP Rajpert-De Meyts E Spagnoli GC et al. The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ. Lab. Invest. 2002 82 775 80.
23. Takahashi K Shichijo S Noguchi M Hirohata M Itoh K. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res. 1995 55 3478 82.
24. Cronwright G Le Blanc K Gotherstrom C Darcy P Ehnman M Brodin B. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res. 2005 65 2207 15.
25. Vaughan HA Svobodova S Macgregor D et al. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin. Cancer Res. 2004 10 8396 404.
26. Bolli M Schultz-Thater E Zajac P et al. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. Int. J. Cancer 2005 115 960 66.
27. Fujita S Wada H Jungbluth AA et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin. Cancer Res. 2004 10 6551 8.
28. Odunsi K Jungbluth AA Stockert E et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 2003 63 6076 83.
29. Hudolin T Juretic A Spagnoli GC et al. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue. Prostate 2006 66 13 18.
30. Jungbluth AA Antonescu CR Busam KJ et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int. J. Cancer 2001 94 252 6.
31. Sahin U Koslowski M Tureci O et al. Expression of cancer testis genes in human brain tumors. Clin. Cancer Res. 2000 6 3916 22.
32. Barrow C Browning J MacGregor D et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin. Cancer Res. 2006 12 764 71.
33. Gibbs P Hutchins AM Dorian KT et al. MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma. Melanoma Res. 2000 10 259 64.
34. Kubuschok B Xie X Jesnowski R et al. Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis. Int. J. Cancer 2004 109 568 75.
35. Rodolfo M Luksch R Stockert E et al. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res. 2003 63 6948 55.
36. Goydos JS Patel M Shih W. NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma. J. Surg. Res. 2001 98 76 80.
37. Dhodapkar MV Osman K Teruya-Feldstein J et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun. 2003 3 9 16.
38. van Rhee F Szmania SM Zhan F et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005 105 3939 44.
39. Gure AO Chua R Williamson B et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin. Cancer Res. 2005 11 8055 62.
40. Konishi J Toyooka S Aoe M et al. The relationship between NY-ESO-1 mRNA expression and clinicopathological features in non-small cell lung cancer. Oncol. Rep. 2004 11 1063 7.
41. Nakada T Noguchi Y Satoh S et al. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun. 2003 3 10 21.
42. Kurashige T Noguchi Y Saika T et al. NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res. 2001 61 4671 4.
43. Sharma P Gnjatic S Jungbluth AA et al. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun. 2003 3 19 31.
44. Wang Y Wu XJ Zhao AL et al. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immun. 2004 4 11 17.
45. Li M Yuan YH Han Y et al. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin. Cancer Res. 2005 11 1809 14.
46. Yakirevich E Sabo E Lavie O Mazareb S Spagnoli GC Resnick MB. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin. Cancer Res. 2003 9 6453 60.
47. Peng JR Chen HS Mou DC et al. Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett. 2005 219 223 32.
48. Tureci O Mack U Luxemburger U et al. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett. 2005 in press
49. Jager E Stockert E Zidianakis Z et al. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int. J. Cancer 1999 84 506 10.
50. Jager D Jager E Knuth A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J. Clin. Pathol. 2001 54 669 74.
51. Jager E Chen YT Drijfhout JW et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 1998 187 265 70.
52. Jager E Nagata Y Gnjatic S et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl Acad. Sci. USA 2000 97 4760 65.
53. Danke NA Koelle DM Yee C Beheray S Kwok WW. Autoreactive T cells in healthy individuals. J. Immunol. 2004 172 5967 72.
54. Gotter J Brors B Hergenhahn M Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp. Med. 2004 199 155 66.
55. Zeng G Aldridge ME Wang Y et al. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int. J. Cancer 2005 114 268 73.
56. Valmori D Souleimanian NE Hesdorffer CS Ritter G Old LJ Ayyoub M. Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses. Clin. Immunol. 2005 117 24 30.
57. Preuss KD Regitz E Neumann F Pfreundschuh M. B-cell epitopes from the cancer testis antigen NY-ESO-1. Int. J. Cancer 2006 118 253.
58. + responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc. Natl Acad. Sci. USA 2004 101 9363 8.
59. Davis ID Chen W Jackson H et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc. Natl Acad. Sci. USA 2004 101 10 697 702.
60. Scanlan MJ Simpson AJ Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004 4 1 15.
61. Scanlan MJ Gure AO Jungbluth AA Old LJ Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 2002 188 22 32.
62. Usener D Gerhardt A Schadendorf D Eichmuller S. Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients. Br. J. Dermatol. 2003 149 282 8.
63. Jager D Stockert E Karbach J et al. Urine antibody against human cancer antigen NY-ESO-1. Cancer Immun. 2002 2 10 18.
64. Campagnolo C Meyers KJ Ryan T et al. Real-time, label-free monitoring of tumor antigen and serum antibody interactions. J. Biochem. Biophys. Methods 2004 61 283 98.
65. Zeng G Wang X Robbins PF Rosenberg SA Wang RF. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc. Natl Acad. Sci. USA 2001 98 3964 9.
66. Huarte E Karbach J Gnjatic S et al. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones. Cancer Immun. 2004 4 15 21.
67. Shackleton MJ Sturrock S MacGreogor D et al. Indolent patterns of disease progression in melanoma patients expressing anti-NY-ESO-1 antibodies. In Cancer Immunosurveillance 1999. 1999 New York Cancer Research Institute 1999 P1 09.
68. Gnjatic S Jager E Chen W et al. CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc. Natl Acad. Sci. USA 2002 99 11 813 18.
69. Held G Matsuo M Epel M et al. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur. J. Immunol. 2004 34 2919 29.
70. Zeng G Li Y El-Gamil M et al. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res. 2002 62 3630 35.
71. Gnjatic S Nagata Y Jager E et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc. Natl Acad. Sci. USA 2000 97 10 917 22.
72. Jackson HM Dimopoulos N Chen Q et al. A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. J. Immunol. Methods 2004 291 51 62.
73. Nagorsen D Scheibenbogen C Marincola FM Letsch A Keilholz U. Natural T cell immunity against cancer. Clin. Cancer Res. 2003 9 4296 303.
74. Valmori D Dutoit V Lienard D et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 2000 60 4499 506.
75. Benlalam H Linard B Guilloux Y et al. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J. Immunol. 2003 171 6283 9.
76. Jager E Karbach J Gnjatic S et al. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. Cancer Immun. 2002 2 12 24.
77. Karbach J Pauligk C Bender A et al. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011. Int. J. Cancer 2006 118 668 74.
78. Jager E Jager D Karbach J et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med. 2000 191 625 30.
79. Zarour HM Storkus WJ Brusic V Williams E Kirkwood JM. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res. 2000 60 4946 52.
80. Zarour HM Maillere B Brusic V et al. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 2002 62 213 18.
81. Valmori D Souleimanian NE Hesdorffer CS Old LJ Ayyoub M. Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals. Clin. Immunol. 2005 117 161 7.
82. Mandic M Castelli F Janjic B et al. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J. Immunol. 2005 174 1751 9.
83. Neumann F Wagner C Kubuschok B Stevanovic S Rammensee HG Pfreundschuh M. Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. Cancer Immunol. Immunother. 2004 53 589 99.
84. Sun Z Lethe B Zhang Y et al. A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors. Cancer Immunol. Immunother. 2005 55 644 52.
85. Wang HY Lee DA Peng G et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004 20 107 18.
86. Wang RF Johnston SL Zeng G Topalian SL Schwartzentruber DJ Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol. 1998 161 3598 606.
87. Wang RF Parkhurst MR Kawakami Y Robbins PF Rosenberg SA. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 1996 183 1131 40.
88. Aarnoudse CA van den Doel PB Heemskerk B Schrier PI. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int. J. Cancer 1999 82 442 8.
89. Rimoldi D Rubio-Godoy V Dutoit V et al. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J. Immunol. 2000 165 7253 61.
90. Rosenberg SA Tong-On P Li Y et al. Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy. J. Immunol. 2002 168 2402 7.
91. Mandic M Almunia C Vicel S et al. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells. Cancer Res. 2003 63 6506 15.
92. Slager EH van der Minne CE Kruse M Krueger DD Griffioen M Osanto S. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes. J. Immunol. 2004 172 5095 102.
93. Slager EH van der Minne CE Goudsmit J et al. Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber. Cancer Gene Ther. 2004 11 227 36.
94. Slager EH Borghi M van der Minne CE et al. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J. Immunol. 2003 170 1490 97.
95. Le Gal FA Ayyoub M Dutoit V et al. Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1. J. Immunother. 2005 28 252 7.
96. Mortarini R Piris A Maurichi A et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res. 2003 63 2535 45.
97. Zhang L Conejo-Garcia JR Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003 348 203 13.
98. Sato E Olson SH Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 2005 102 18 538 43.
99. Antony PA Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J. Immunother. 2005 28 120 28.
100. Berendt MJ North RJ. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J. Exp. Med. 1980 151 69 80.
101. Mills KH McGuirk P. Antigen-specific regulatory T cells - their induction and role in infection. Semin. Immunol. 2004 16 107 17.
102. Fontenot JD Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. 2005 6 331 7.
103. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004 22 531 62.
104. Thornton AM Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 1998 188 287 96.
105. Wang HY Peng G Guo Z Shevach EM Wang RF. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J. Immunol. 2005 174 2661 70.
106. Nishikawa H Jager E Ritter G Old LJ Gnjatic S. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 2005 106 1008 11.
107. Mischo A Kubuschok B Ertan K et al. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int. J. Cancer 2006 118 696 703.
108. Palucka AK Laupeze B Aspord C et al. Immunotherapy via dendritic cells. Adv. Exp. Med. Biol. 2005 560 105 14.
109. Rimmelzwaan GF Nieuwkoop N Brandenburg A et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 2000 19 1180 87.
110. Sjolander A Cox JC Barr IG. ISCOMs: an adjuvant with multiple functions. J. Leukoc. Biol. 1998 64 713 23.
111. Morein B Sundquist B Hoglund S Dalsgaard K Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984 308 457 60.
112. Lenarczyk A Le TT Drane D et al. ISCOM based vaccines for cancer immunotherapy. Vaccine 2004 22 963 74.
113. Schnurr M Chen Q Shin A et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005 105 2465 72.
114. Jager E Gnjatic S Nagata Y et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl Acad. Sci. USA 2000 97 12 198 203.
115. Shackleton M Davis ID Hopkins W et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 2004 4 9 19.
116. Chen Q Jackson H Shackleton M et al. Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination. Cancer Immun. 2005 5 5 11.
117. Khong HT Yang JC Topalian SL et al. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J. Immunother. 2004 27 472 7.
118. Maraskovsky E Sjolander S Drane DP et al. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin. Cancer Res. 2004 10 2879 90.
119. + T cells efficiently in cancer patients. J. Immunother. 2006 in press
120. Speiser DE Lienard D Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 2005 115 739 46.
121. Seino K Fujii S Harada M et al. Valpha14 NKT cell-mediated anti-tumor responses and their clinical application. Springer Semin. Immunopathol. 2005 27 65 74.
122. Fujii S Shimizu K Smith C Bonifaz L Steinman RM. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 2003 198 267 79.
123. Silk JD Hermans IF Gileadi U et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J. Clin. Invest. 2004 114 1800 811.
124. Giaccone G Punt CJ Ando Y et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 2002 8 3702 9.
125. Nieda M Okai M Tazbirkova A et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004 103 383 9.
126. Ishikawa A Motohashi S Ishikawa E et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 2005 11 1910 17.
127. Chang DH Osman K Connolly J et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 2005 201 1503 17.
128. Alegre ML Frauwirth KA Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat. Rev. Immunol. 2001 1 220 28.
129. van Elsas A Hurwitz AA Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 1999 190 355 66.
130. Attia P Phan GQ Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005 23 6043 53.
131. Ribas A Camacho LH Lopez-Berestein G et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol. 2005 23 8968 77.
132. Hodi FS Mihm MC Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 2003 100 4712 17.
133. Sanderson K Scotland R Lee P et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 2005 23 741 50.
134. Zhou G Drake CG Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006 107 628 36.
135. Curiel TJ Coukos G Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004 10 942 9.
136. Viguier M Lemaitre F Verola O et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 2004 173 1444 53.
137. Chattopadhyay S Mehrotra S Chhabra A Hegde U Mukherji B Chakraborty NG. Effect of CD4+CD25+ and CD4+CD25- T regulatory cells on the generation of cytolytic T cell response to a self but human tumor-associated epitope in vitro. J. Immunol. 2006 176 984 90.
138. Ercolini AM Ladle BH Manning EA et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 2005 201 1591 602.
139. Dannull J Su Z Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005 115 3623 33.
140. Pasare C Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003 299 1033 6.
141. Peng G Guo Z Kiniwa Y et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005 309 1380 84.
142. Ganss R Arnold B Hammerling GJ. Mini-review: overcoming tumor-intrinsic resistance to immune effector function. Eur. J. Immunol. 2004 34 2635 41.
143. Ryschich E Schmidt J Hammerling GJ Klar E Ganss R. Transformation of the microvascular system during multistage tumorigenesis. Int. J. Cancer 2002 97 719 25.
144. Luster AD Alon R von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 2005 6 1182 90.
145. Lugade AA Moran JP Gerber SA Rose RC Frelinger JG Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 2005 174 7516 23.
146. Chakraborty M Abrams SI Coleman CN Camphausen K Schlom J Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 2004 64 4328 37.
147. Scott AM Liu Z Murone C et al. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. Cancer Immun. 2005 5 3 14.
148. Niemeyer P Tureci O Eberle T Graf N Pfreundschuh M Sahin U. Expression of serologically identified tumor antigens in acute leukemias. Leuk. Res. 2003 27 655 60.
149. Mashino K Sadanaga N Tanaka F et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br. J. Cancer 2001 85 713 20.
150. Sahin U Tureci O Chen YT et al. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int. J. Cancer 1998 78 387 9.
151. Chitale DA Jungbluth AA Marshall DS et al. Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray. Mod. Pathol. 2005 18 119 26.
152. Kienstra MA Neel HB Strome SE Roche P. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 2003 25 457 63.
153. Luo G Huang S Xie X et al. Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun. 2002 2 11 20.
154. Korangy F Ormandy LA Bleck JS et al. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin. Cancer Res. 2004 10 4332 41.
155. Zhang WM Xiao G Xie D Zhang M Guo AL Wen JM. [Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma]. Ai Zheng 2005 24 622 6.
156. Shang XY Chen HS Zhang HG et al. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin. Cancer Res. 2004 10 6946 55.
157. Prasad ML Jungbluth AA Patel SG Iversen K Hoshaw-Woodard S Busam KJ. Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck. Head Neck 2004 26 1053 7.
158. Wolfl M Jungbluth AA Garrido F et al. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol. Immunother. 2005 54 400 406.
159. Wang Y Liang Z Yuan YH et al. [Expression of multiple cancer-testis antigen genes in non-small cell lung cancer treated by chemotherapy prior surgery]. Zhonghua Yi Xue Za Zhi 2004 84 464 8.
160. Akcakanat A Kanda T Tanabe T et al. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy. Int. J. Cancer 2006 118 123 8.
161. Akcakanat A Kanda T Koyama Y et al. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother. Pharmacol. 2004 54 95 100.
162. Fossa A Berner A Fossa SD Hernes E Gaudernack G Smeland EB. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 2004 59 440 47.
163. Neumann E Engelsberg A Decker J et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res. 1998 58 4090 95.
164. Yuasa T Okamoto K Kawakami T Mishina M Ogawa O Okada Y. Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue. J. Urol. 2001 165 1790 94.
165. Maio M Coral S Sigalotti L et al. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J. Clin. Endocrinol. Metab. 2003 88 748 54.
166. Resnick MB Sabo E Kondratev S Kerner H Spagnoli GC Yakirevich E. Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas. Int. J. Cancer 2002 101 190 95.
167. Chen JL Dunbar PR Gileadi U et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J. Immunol. 2000 165 948 55.
168. Zeng G Touloukian CE Wang X Restifo NP Rosenberg SA Wang RF. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol. 2000 165 1153 9.
169. + T cell responses to NY-ESO-1. J. Immunol. 2006 176 in press